TLR3 and bacterial infectious disease: To validate the earlier findings from a mouse chronic biofilm infection model that evaluated i.v. treatment with activated MSC (10), we conducted a pilot study of TLR3 activated MSC safety and efficacy in pet dogs with spontaneous, chronic (minimum 4 weeks duration), drug-resistant bacterial infections in a variety of different sites, including soft tissues and joints.